Subcutaneous panniculitis-like T-cell lymphoma after rituximab.
Jason C
JC
Sluzevich
Matthew R
MR
Hall
Vivek
V
Roy
D000368:Aged; D000743:Anemia, Hemolytic / Q000150:complications; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008297:Male; D015434:Panniculitis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D000069283:Rituximab; D013601:T-Lymphocytes / Q000276:immunology
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D003520:Cyclophosphamide